Working… Menu

LAMA2-related Muscular Dystrophy Brain Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01952028
Recruitment Status : Withdrawn
First Posted : September 27, 2013
Last Update Posted : March 7, 2018
Congenital Muscle Disease International Registr
Information provided by (Responsible Party):
Cure CMD

Brief Summary:
Laminin alpha-2 (LAMA2)-related muscular dystrophy (LAMA2-MD, Merosin Deficient CMD) is a form of congenital muscular dystrophy (CMD). A person with LAMA2-MD will have changes on brain imaging (MRI), a decrease or absence of the protein merosin (laminin 211) on muscle or skin biopsy and changes in the LAMA2 gene that are inherited from both parents. Several studies have described the changes on brain MRI. Brain changes on MRI do not correlate with the partial reduction or absence of merosin on muscle or skin biopsy. 8-30% of people with LAMA2-MD develop seizures. The types of seizures, electroencephalogram changes and common treatment regimens have not been characterized. This study will review the magnetic resonance imaging (MRI) changes, determine whether certain brain MRI changes are linked to seizures and define the common seizure treatment regimens.

Condition or disease
LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A)

Detailed Description:

LAMA2-MD is a congenital muscular dystrophy (CMD) subtype caused by mutations in the laminin alpha 2 gene. LAMA2-MD may present clinically as an early onset, severe phenotype or a late onset limb girdle phenotype. The early onset form is most commonly associated with a complete absence of merosin on muscle biopsy with profound neonatal hypotonia, possible respiratory distress and feeding difficulties while the late onset form presents with proximal muscle weakness, contractures and is able to achieve walking. In both early and late onset forms, brain white matter abnormalities have been described on brain MRI and approximately 8-30% develop a seizure disorder. On magnetic resonance (MR) spectroscopy, white matter changes are shown to be due to increased water content rather than areas of demyelination. Both, non-ambulant and ambulant patients may develop respiratory insufficiency requiring non-invasive ventilation and scoliosis.

Although several studies have evaluated the correlation between brain MRI white matter changes and cognition, no studies to date have provided a systematic evaluation of brain imaging, electrophysiologic testing and seizures in patients identified by molecular or immunohistochemical testing to have LAMA2-MD.

Layout table for study information
Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A LAMA2-related Muscular Dystrophy Study: Brain Magnetic Resonance Imaging (MRI)and Brain Electrophysiology Evaluation
Study Start Date : November 2013
Estimated Primary Completion Date : November 2014
Estimated Study Completion Date : December 2014

Primary Outcome Measures :
  1. Identify and grade the structural brain abnormalities observed on MRI [ Time Frame: up to 5 months ]
    Both single and longitudinal brain MRIs will be retrieved with patient consent from hospitals within the United States. Two trained neuroradiologists will evaluate de-identified brain MRIs using a pre-determined scoring system to identify and classify structural abnormalities.

Secondary Outcome Measures :
  1. Seizure History [ Time Frame: up to 8 months ]
    To obtain a seizure history on all individuals with LAMA2-MD who have had a seizure, including: type of seizures, age of seizure onset, seizure frequency, need for mechanical ventilation, seizure medications, and need for emergency room (ER) visit or hospitalization.

  2. Evaluation of baseline and diagnostic electroencephalograms [ Time Frame: up to 8 months ]
    Both baseline and diagnostic electroencephalograms (EEG) will be obtained with patient consent from hospitals within the United States. An epileptologist will review de-identified EEG recordings to identify and classify abnormalities using a predetermined scoring system.

  3. Examine the association between brain MRI structural abnormalities and EEG findings [ Time Frame: up to 11 months ]
    Compare the frequency of various grades of brain MRI abnormalities in individuals with LAMA2-MD with and without seizures. Identify any association between MRI abnormality and type of seizure.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Inclusion Criteria:

  • Genetic confirmation of 2 variants in LAMA2 gene OR muscle biopsy with complete absence of merosin
  • Complete authorization to obtain medical records for Congenital Muscle Disease International Registry
  • Complete authorization to obtain medical records for National Institutes of Health (NIH)
  • Reside in United States or Canada
  • Complete registration and intake survey in the Congenital Muscle Disease International Registry

Exclusion Criteria:

- Individuals with LAMA2-MD who have not had a brain MRI

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01952028

Layout table for location information
United States, California
San Pedro, California, United States, 90732
Sponsors and Collaborators
Cure CMD
Congenital Muscle Disease International Registr
Layout table for investigator information
Principal Investigator: Anne Rutkowski, MD, PhD Cure CMD

Layout table for additonal information
Responsible Party: Cure CMD Identifier: NCT01952028    
Other Study ID Numbers: CMDIR-003
First Posted: September 27, 2013    Key Record Dates
Last Update Posted: March 7, 2018
Last Verified: October 2015
Keywords provided by Cure CMD:
Congenital Muscular Dystrophy
Merosin Deficient
brain white matter abnormalities
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn